Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options

Levothyroxine (LT4) therapy has a long history, a well-defined pharmacological profile and a favourable safety record in the alleviation of hypothyroidism. However, questions remain in defining the threshold for the requirement of treatment in patients with subclinical hypothyroidism, assessing the...

Full description

Bibliographic Details
Main Authors: Rudolf Hoermann, John E M Midgley, Rolf Larisch, Johannes W Dietrich
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2019-08-01
Series:Drugs in Context
Subjects:
Online Access:https://www.drugsincontext.com/individualised-requirements-for-optimum-treatment-of-hypothyroidism:-complex-needs,-limited-options/
id doaj-7a37aa97e1a04b3d83a5cac22483a1c3
record_format Article
spelling doaj-7a37aa97e1a04b3d83a5cac22483a1c32020-11-24T21:55:28ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982019-08-01811810.7573/dic.212597Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited optionsRudolf HoermannJohn E M MidgleyRolf LarischJohannes W DietrichLevothyroxine (LT4) therapy has a long history, a well-defined pharmacological profile and a favourable safety record in the alleviation of hypothyroidism. However, questions remain in defining the threshold for the requirement of treatment in patients with subclinical hypothyroidism, assessing the dose adequacy of the drug, and selecting the best treatment mode (LT4 monotherapy versus liothyronine [LT3]/LT4 combinations) for subpopulations with persisting complaints. Supplied as a prodrug, LT4 is enzymatically converted into the biologically more active thyroid hormone, triiodothyronine (T3). Importantly, tetraiodothyronine (T4) to T3 conversion efficiency may be impaired in patients receiving LT4, resulting in a loss of thyroid-stimulating hormone (TSH)-mediated feedforward control of T3, alteration of the interlocking equilibria between serum concentrations of TSH, free thyroxine (FT4), and free triiodothyonine (FT3), and a decrease in FT3 to FT4 ratios. This downgrades the value of the TSH reference system derived in thyroid health for guiding the replacement dose in the treatment situation. Individualised conditionally defined setpoints may therefore provide appropriate biochemical targets to be clinically tested, together with a stronger focus on clinical presentation and future endpoint markers of tissue thyroid state. This cautionary note encompasses the use of aggregated statistical data from clinical trials which are not safely applicable to the individual level of patient care under these circumstances.https://www.drugsincontext.com/individualised-requirements-for-optimum-treatment-of-hypothyroidism:-complex-needs,-limited-options/ergodicityhypothyroidismLT4 treatmentpersonalised medicinesetpoint
collection DOAJ
language English
format Article
sources DOAJ
author Rudolf Hoermann
John E M Midgley
Rolf Larisch
Johannes W Dietrich
spellingShingle Rudolf Hoermann
John E M Midgley
Rolf Larisch
Johannes W Dietrich
Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
Drugs in Context
ergodicity
hypothyroidism
LT4 treatment
personalised medicine
setpoint
author_facet Rudolf Hoermann
John E M Midgley
Rolf Larisch
Johannes W Dietrich
author_sort Rudolf Hoermann
title Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
title_short Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
title_full Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
title_fullStr Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
title_full_unstemmed Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
title_sort individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
publisher BioExcel Publishing Ltd
series Drugs in Context
issn 1740-4398
1740-4398
publishDate 2019-08-01
description Levothyroxine (LT4) therapy has a long history, a well-defined pharmacological profile and a favourable safety record in the alleviation of hypothyroidism. However, questions remain in defining the threshold for the requirement of treatment in patients with subclinical hypothyroidism, assessing the dose adequacy of the drug, and selecting the best treatment mode (LT4 monotherapy versus liothyronine [LT3]/LT4 combinations) for subpopulations with persisting complaints. Supplied as a prodrug, LT4 is enzymatically converted into the biologically more active thyroid hormone, triiodothyronine (T3). Importantly, tetraiodothyronine (T4) to T3 conversion efficiency may be impaired in patients receiving LT4, resulting in a loss of thyroid-stimulating hormone (TSH)-mediated feedforward control of T3, alteration of the interlocking equilibria between serum concentrations of TSH, free thyroxine (FT4), and free triiodothyonine (FT3), and a decrease in FT3 to FT4 ratios. This downgrades the value of the TSH reference system derived in thyroid health for guiding the replacement dose in the treatment situation. Individualised conditionally defined setpoints may therefore provide appropriate biochemical targets to be clinically tested, together with a stronger focus on clinical presentation and future endpoint markers of tissue thyroid state. This cautionary note encompasses the use of aggregated statistical data from clinical trials which are not safely applicable to the individual level of patient care under these circumstances.
topic ergodicity
hypothyroidism
LT4 treatment
personalised medicine
setpoint
url https://www.drugsincontext.com/individualised-requirements-for-optimum-treatment-of-hypothyroidism:-complex-needs,-limited-options/
work_keys_str_mv AT rudolfhoermann individualisedrequirementsforoptimumtreatmentofhypothyroidismcomplexneedslimitedoptions
AT johnemmidgley individualisedrequirementsforoptimumtreatmentofhypothyroidismcomplexneedslimitedoptions
AT rolflarisch individualisedrequirementsforoptimumtreatmentofhypothyroidismcomplexneedslimitedoptions
AT johanneswdietrich individualisedrequirementsforoptimumtreatmentofhypothyroidismcomplexneedslimitedoptions
_version_ 1725862532472635392